| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7ddc4774cf5f8a0bda44a780d73c53d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0034 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-02 |
| filingDate |
2013-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6094ba67d5557d95dc3cca2c90e72191
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dff0dab29cf0bb819901d80347ea0ef8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89eaee0dc5f2407977d26d31671e841e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_102f323829ea35e610998ca58d10f686
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1be5e1621acb6d121ae86a42bbeaf0b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7997126de7f7e531e4bb5a8f94f1d3a2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17a13e8d138e16c7d0b3da6595f7e375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f20f037eda32f40e66834580b4d40a8d |
| publicationDate |
2014-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20140102939-A |
| titleOfInvention |
Pharmaceutical composition for intravaginal administration comprising phosphodiesterase-5 inhibitor or pharmaceutically acceptable salt thereof |
| abstract |
The present invention relates to a pharmaceutical composition for intravaginal administration comprising a phosphodiesterase-5 inhibitor or a pharmaceutically acceptable salt of the same as an active ingredient; and hard fat as a base agent for a suppository. The pharmaceutical composition for intravaginal administration of the present invention has excellent stability and is locally applied to a targeted organ so that side effects on the entire body of the PDE-5 inhibitor can be reduced. Drug concentration in the reproductive organ and uterus is maximized, and the PDE-5 inhibitor exhibits improved medicinal effects, so that the pharmaceutical composition can be practically used in alleviating female menopausal disorders, treating sexual excitement disorders, and increasing fertilization probability and pregnancy sustaining rates. |
| priorityDate |
2013-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |